Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of ARRY-380 in Patients With Advanced HER2+ Cancer

Trial Profile

A Study of ARRY-380 in Patients With Advanced HER2+ Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs Tucatinib (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Endometrial cancer; Lung cancer; Ovarian cancer; Prostate cancer; Salivary gland cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Pharmacokinetics
  • Sponsors Array BioPharma
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 04 Jan 2017 Results analysing maximum tolerated dose(MTD), pharmacokinetics and antitumor activity published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 07 Oct 2013 Final results will be presented at the American Association for Cancer Research Special Conference on Advances in Breast Cancer Research according to an Oncothyreon media release. Results were also reported in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top